Meta-Analysishigh evidence
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
The lancet. Diabetes & endocrinology·August 7, 2026·PMID 42567173
Why it mattersPatients with cardio-kidney-metabolic disease face high risks of kidney function loss and cardiovascular events. This pooled analysis provides robust, participant-level evidence that semaglutide—across different formulations and doses—significantly reduces clinically important kidney outcomes in a broad population, including those without diabetes. The findings support considering semaglutide for kidney protection beyond its glycemic and weight-loss effects.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled